SUMMARY Children from the UKALL V trial were studied to assess the clinical importance of myelosuppression during uninterrupted 'maintenance' treatment of 'standard risk' lymphoblastic leukaemia. Those receiving daily 6-mercaptopurine and weekly methotrexate who were in first remission 20 months from diagnosis were divided into two groups on the basis of whether or not they had ever had an absolute neutrophil count of <05 x 10 /l recorded during maintenance treatment up to that time. Of 105 evaluable children, 45 (43%) became neutropenic at least once, and 60 (57%) did not. Seven (16%) of the neutropenic group subsequently relapsed compared with 27 (45%o) of the remainder. This difference was still significant if the analysis was stratified by total treatment time (two or three years), age, sex, or diagnostic white cell count. Seven (16%) neutropenic children died in remission, compared with one (2%) of the non-neutropenic children.
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Therapeutic myelosuppression during standard maintenance treatment of 'standard risk' lymphoblastic leukaemia is associated with increased toxicity but a reduced risk of relapse. The unexplained improvement in long term survival in the United Kingdom in recent years may in large part be due to this.
Current conventional treatment of other than 'high risk' childhood lymphoblastic leukaemia includes a long phase of continuing 'maintenance' chemotherapy. This usually consists of daily 6-mercaptopurine and weekly oral methotrexate, together with occasional pulses of vincristine and prednisolone.
How important this phase of treatment is may depend on the nature and intensity of remission induction, consolidation and/or intensive 'blocks' of chemotherapy given in addition. From the observed incidence of relapse in early trials without prolonged maintenance,' however, and in patients who default from follow up, there can be little doubt that for many children on various regimens it is important.
Further evidence is available from UKALL V, a recent United Kingdom Medical Research Council (MRC) trial which compared three different ways of giving the same cumulative dose of 6-mercaptopurine and methotrexate in maintenance. The results were not the same, and giving 6-mercaptopurine continuously appeared to be associated with more effective disease control than intermittent dosing.2 The basic design of a succeeding MRC trial, UKALL VIII, did not appear to differ substantially from the UKALL V 'continuous' arm, but none the less produced a sustained and striking improvement in long term disease free survival, which has yet to be explained. 3 An impression gained by clinicians involved in UKALL VIII was of a greater incidence of treatment induced myelosuppression and morbidity during maintenance. This appeared to be due to higher cumulative doses of 6-mercaptopurine and methotrexate being given as a result of more rigidly defined prescribing criteria than in previous trials. 1231 If more children on UKALL VIII became neutropenic and more survived their disease, it seemed obvious to ask if the two phenomena could be related. To answer this question we chose to examine the 'continuous' arm of UKALL V. The design was very similar to UKALL VIII, but we anticipated there would be a larger proportion of patients who did not become neutropenic giving more equal group sizes for analysis. This report describes our findings.
Patients and methods
All children in the United Kingdom with 'standard risk' lymphoblastic leukaemia between the ages of 1 and 14 years, who had no meningeal disease or mediastinal mass, and who had a diagnostic white cell count <20 x 109/l were eligible for UKALL V.
The regimen has been described in detail elsewhere,2 but briefly consisted of remission induction with four doses of vincristine, four weeks of prednisolone, and four doses of L-asparaginase (10 000 U/M2) after marrow recovery. This was followed by cranial irradiation, five doses of intrathecal methotrexate, daily 6-mercaptopurine (50 mg/mi2), and two further weeks of vincristine and steroid treatment before all patients were randomised to one of three continuing (maintenance) regimens. The 'continuous' arm consisted of 12 week cycles with a pulse of vincristine and steroids every six weeks, weekly oral methotrexate (20 mg/M2), and daily 6-mercaptopurine with a target dose of 50-70 mg/mi2. Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia 1233 The timing of neutropenia did not seem important in terms of whether it occurred within the first nine months of treatment or later, nor did the frequency of neutropenic episodes in terms of the number of recorded neutrophil counts <0.5 x 109/1 provided it was less than three. Children who had profound neutropenia on more than four occasions (there were only four so the numbers are very small) may paradoxically have a higher relapse rate. Two relapsed, and comparison with those who became neutropenic one, two, or three times gives 2 x p=001; the observed:expected ratio was 2-7.
The method of defining neutropenia did seem important, and no difference in the relapse rate of the 105 could be seen if the patients were divided around a threshold neutrophil count of 1-0 x 109/l, or if a median value for each patient was calculated.
Discussion
The clear implication from this cohort study is that treatment induced myelosuppression during continuing (maintenance) therapy for standard risk lymphoblastic leukaemia is associated with greater toxicity but better disease control. Most of the episodes of neutropenia observed would have been due to chemotherapy as another major myelosuppressant, co-trimoxazole, was not used in UKALL V.
The findings support the hypothesis that much of the improvement in long term survival seen in the United Kingdom after 1980 is due to increased cytotoxicity of 6- 
